ライフサイエンスコーパス: healthcare cost

1 m a societal perspective (healthcare and non-healthcare costs).

2 ing their hospitalization and increasing the healthcare cost.

3 major driver of overall reductions in direct healthcare cost.

4 ed infections and significant contributor to healthcare cost.

5 rove antimicrobial stewardship, and decrease healthcare costs.

6 discount rate, visual acuity before CXL, and healthcare costs.

7 ucing the duration of general anesthesia and healthcare costs.

8 ignificantly contribute to asthma-associated healthcare costs.

9 ted with poor patient outcomes and increased healthcare costs.

10 sociated with high morbidity, mortality, and healthcare costs.

11 rtality from diabetes and CVD while reducing healthcare costs.

12 e a major cause of morbidity, mortality, and healthcare costs.

13 esource utilization and reducing unnecessary healthcare costs.

14 sociated with poor patient outcomes and high healthcare costs.

15 0.5 million and save $8.0 million in averted healthcare costs.

16 usal connection between smoking behavior and healthcare costs.

17 and provides a basis for modeling impact on healthcare costs.

18 ialysis unit may improve outcomes and reduce healthcare costs.

19 atients' quality of life, patient safety and healthcare costs.

20 cal complications have substantial impact on healthcare costs.

21 reduce overuse of colonoscopy and associated healthcare costs.

22 cations, increasing demand for treatment and healthcare costs.

23 ed quality of life and mortality, and higher healthcare costs.

24 tay and therefore favors patient outcome and healthcare costs.

25 raella communa on the number of patients and healthcare costs.

26 r benefits for infant morbidity patterns and healthcare costs.

27 ficant postoperative morbidity and increased healthcare costs.

28 ntly associated with increased morbidity and healthcare costs.

29 d to longer hospitalization times and higher healthcare costs.

30 RSA), limits treatment options and increases healthcare costs.

31 pact on patient health, quality of life, and healthcare costs.

32 nue to increase as well as the corresponding healthcare costs.

33 gest a rising disease burden, morbidity, and healthcare costs.

34 ospitalizations resulted in >$1.3 billion in healthcare costs.

35 Cost-consequence analysis of fall-related healthcare costs.

36 ncluded type/duration of hospitalization and healthcare costs.

37 e significant impact on patient survival and healthcare costs.

38 e care in the ICU could significantly reduce healthcare costs.

39 .80), and there was no difference in overall healthcare costs.

40 patient-centered care while limiting rising healthcare costs.

41 can both improve health outcomes and reduce healthcare costs.

42 unt for a significant percentage of hospital healthcare costs.

43 n negatively affect health and may impact on healthcare costs.

44 poor outcomes for individuals and increased healthcare costs.

45 ity, mortality, length of hospital stay, and healthcare costs.

46 ilure, with adverse effects on prognosis and healthcare costs.

47 the gifts of whole-blood donors or minimize healthcare costs.

48 n on society in terms of both lives lost and healthcare costs.

49 home or as an outpatient, ultimately saving healthcare costs.

50 een worldwide emphasis on the containment of healthcare costs.

51 iated with repeat catheterization and higher healthcare costs.

52 ading to longer hospital stays and increased healthcare costs.

53 quality vs. the societal mandate to control healthcare costs.

54 in terms of morbidity, quality of life, and healthcare costs.

55 necessary hospital admissions and associated healthcare costs.

56 tice system while only moderately increasing healthcare costs.

57 idity, higher mortality rates, and increased healthcare costs.

58 e United States accounts for about 1% of all healthcare costs.

59 se both morbidity and mortality and inflates healthcare costs.

60 sepsis, reduce antibiotic overuse, and lower healthcare costs.

61 experience low survival rates and incur high healthcare costs.

62 c delay, disease progression and significant healthcare costs.

63 ers' industry payments with Medicare data on healthcare costs.

64 lion QALYs, and save $39.7 billion in formal healthcare costs.

65 s limited, despite increasing prevalence and healthcare costs.

66 ted 374,766 providers' industry payments and healthcare costs.

67 pact on life expectancy, quality of life and healthcare costs.

68 scular drug innovation, quality of care, and healthcare costs.

69 ses of preventable morbidity, mortality, and healthcare costs.

70 lem, with enormous individual, societal, and healthcare costs.

71 hat significantly increases patient harm and healthcare costs.

72 ll-being and lower morbidity, mortality, and healthcare costs.

73 ciated with fewer hospitalizations and lower healthcare costs.

74 n years) and per-person lifetime HIV-related healthcare costs.

75 cision making and may contribute to lowering healthcare costs.

76 hildren's growth and unnecessarily impact on healthcare costs.

77 9144 dollars; P=0.04; mean per-subject total healthcare costs, 15,384 dollars versus 19,728 dollars;

78 1) early mobilization is safe and may reduce healthcare costs, 2) safety criteria should be provided,

79 and infant life expectancy (LE) and lifetime healthcare costs (2008 US dollars [USD]).

80 HIV prevalence settings due to reductions in healthcare costs, absenteeism, and staff turnover.

81 As the national debate about healthcare costs, access, and quality continues, we will

82 nes can prove frustrating and increases both healthcare cost and patient morbidity.

83 nplanned hospital visits using data from the Healthcare Cost and Utilization Project (325,811 colonos

84 onal cost estimates were calculated from the Healthcare Cost and Utilization Project (HCUP) Nationwid

85 for California in 2011 available through the Healthcare Cost and Utilization Project (HCUP) were link

86 ent Databases (SID) developed as part of the Healthcare Cost and Utilization Project (HCUP), covering

87 S hospital discharge database available, the Healthcare Cost and Utilization Project (HCUP), to study

88 from the US State Inpatient Databases of the Healthcare Cost and Utilization Project 2003-2009, we qu

89 Arizona, California, and Washington from the Healthcare Cost and Utilization Project and influenza su

90 t surgical procedures were grouped using the Healthcare Cost and Utilization Project Clinical Classif

91 MRI utilization was measured by Healthcare Cost and Utilization Project criteria.

92 d Agency for Healthcare Research and Quality/Healthcare Cost and Utilization Project data from 43 Sta

93 d unplanned hospital visits calculated using Healthcare Cost and Utilization Project data showed sign

94 Among eligible states participating in Healthcare Cost and Utilization Project Data State Inpat

95 Using Healthcare Cost and Utilization Project Data State Inpat

96 round incidence of intussusception by use of Healthcare Cost and Utilization Project data.

97 The Healthcare Cost and Utilization Project database, a nati

98 Using the Healthcare Cost and Utilization Project database, we per

99 e reimbursement databases, RED Book, and the Healthcare Cost and Utilization Project database.

100 Data were obtained from the 1996 and 1997 Healthcare Cost and Utilization Project database.

101 ent and emergency department visits from the Healthcare Cost and Utilization Project for California,

102 acute care hospital discharge data from the Healthcare Cost and Utilization Project for patients who

103 Nationwide Inpatient Sample provided by the Healthcare Cost and Utilization Project from the Agency

104 d from the 2003 Nationwide Inpatient Sample, Healthcare Cost and Utilization Project from the Agency

105 d with hospital discharge data from the 2014 Healthcare Cost and Utilization Project National Inpatie

106 nts undergoing MIPD were identified from the Healthcare Cost and Utilization Project National Inpatie

107 s-sectional analysis was performed using the Healthcare Cost and Utilization Project National Inpatie

108 METHODS AND The Healthcare Cost and Utilization Project National Readmis

109 The 2016 Healthcare Cost and Utilization Project Nationwide Inpat

110 In this study based on the Healthcare Cost and Utilization Project Nationwide Inpat

111 Retrospective cohort study using the Healthcare Cost and Utilization Project Nationwide Inpat

112 DATA AND The Healthcare Cost and Utilization Project Nationwide Inpat

113 ed the 2014 State Inpatient Databases of the Healthcare Cost and Utilization Project of 14 states to

114 the State Inpatient Database, a part of the Healthcare Cost and Utilization Project of the Agency fo

115 from the Nationwide Inpatient Sample via the Healthcare Cost and Utilization Project of the Agency fo

116 surgical visit for infection) using the 2010 Healthcare Cost and Utilization Project State Ambulatory

117 Acute care hospitals in the Healthcare Cost and Utilization Project State Inpatient

118 t/urgent surgeries were identified using the Healthcare Cost and Utilization Project State Inpatient

119 trative data from the California and Florida Healthcare Cost and Utilization Project State Inpatient

120 mapped onto 14,568 ICD9 diagnosis codes from Healthcare Cost and Utilization Project State Inpatient

121 Data from the Healthcare Cost and Utilization Project State Inpatient

122 We queried the Healthcare Cost and Utilization Project State Inpatient

123 the 2002 Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project to estimate the

124 used the Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project to estimate the

125 The Healthcare Cost and Utilization Project was used to iden

126 Data from the 1993 Healthcare Cost and Utilization Project were analyzed to

127 aims data from the 2014 New York and Florida Healthcare Cost and Utilization Project were used to ide

128 tudy of inpatient delivery admissions in the Healthcare Cost and Utilization Project's California Sta

129 t study analyzed all 17672 patients from the Healthcare Cost and Utilization Project's National Inpat

130 Cross-sectional study based on the Healthcare Cost and Utilization Project's Nationwide Inp

131 We used data from the Healthcare Cost and Utilization Project's Nationwide Inp

132 between 2001 and 2008 at US hospitals in the Healthcare Cost and Utilization Project's Nationwide Inp

133 The Healthcare Cost and Utilization Project's Nationwide Rea

134 Data were obtained from the Healthcare Cost and Utilization Project's State Inpatien

135 fied from the 2007-2013 New York and Florida Healthcare Cost and Utilization Project's State Inpatien

136 data set (Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project).

137 By using the Healthcare Cost and Utilization Project, National Inpati

138 s study, we analyzed inpatient data from the Healthcare Cost and Utilization Project, outpatient data

139 the National Inpatient Sample (NIS) from the Healthcare Cost and Utilization Project, we examined tre

140 nd 2010 Nationwide Inpatient Sample from the Healthcare Cost and Utilization Project--a 20% sample of

141 l pacemaker implantation in the 2004 to 2008 Healthcare Cost and Utilization Project-Nationwide Inpat

142 Data were used from the Healthcare Cost and Utilization Project-State Inpatient

143 ida and New York in 2013 using data from the Healthcare Cost and Utilization Project.

144 ing the Nationwide Inpatient Sample from the Healthcare Cost and Utilization Project.

145 from the Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project.

146 ent Databases between 2003 and 2007 from the Healthcare Cost and Utilization Project.

147 the Clinical Classifications Software of the Healthcare Cost and Utilization Project.

148 Using data from the Healthcare Cost and Utilization Projects Nationwide Inpa

149 nterval, 0.6-1.0 billion dollars) in averted healthcare costs and $2.5 billion dollars (95% uncertain

150 aternal fever is associated with both excess healthcare costs and an increased risk of adverse matern

151 However, household healthcare costs and costs for medicines were significan

152 response to national interest in controlling healthcare costs and eliminating unnecessarily expensive

153 With ever-escalating healthcare costs and expectations for faster recovery, a

154 iveness analyses are planned to evaluate the healthcare costs and health outcomes of the approach.

155 ng may more precisely tailor therapy, reduce healthcare costs and improve patient outcome over the ne

156 d (CON) regulation was introduced to control healthcare costs and improve quality of care in part by

157 We dissect the healthcare costs and lost productivity caused by food in

158 om a societal perspective including informal healthcare costs and lost productivity, respective ICERs

159 AKI is associated with increased healthcare costs and mortality.

160 We aimed to estimate the prevalence, healthcare costs and number of deaths among people with

161 veloped using real-world evidence to compare healthcare costs and quality-adjusted life years (QALYs)

162 ntial effect of improved bundle adherence on healthcare costs and quality-adjusted life-years in the

163 is the additional need to reduce unnecessary healthcare costs and radiation exposure.

164 nsated CHF with nesiritide may lead to lower healthcare costs and reduced mortality compared to treat

165 ult in significant morbidity, mortality, and healthcare costs and should be a focus of future surveil

166 This has implications for healthcare costs and the future of the practice of cardi

167 Healthcare Costs and Utilization Project and a comparati

168 e Agency for Healthcare Research and Quality Healthcare Costs and Utilization Project State Inpatient

169 spective analysis of administrative database-Healthcare Costs and Utilization Project's Nationwide In

170 yzed direct costs from a funder perspective (healthcare costs) and from a societal perspective (healt

171 associated with disease progression, higher healthcare cost, and increased mortality.

172 life, creates billions of dollars of annual healthcare costs, and accounts for approximately 20% of

173 a chronic condition with high morbidity and healthcare costs, and cockroach allergens are an establi

174 onary complications on clinical outcomes and healthcare costs, and establish an algorithm that will h

175 ient dignity, increases nursing workload and healthcare costs, and exacerbates morbidity through derm

176 bidity, length of hospitalization, increased healthcare costs, and increased mortality.

177 seem to be a driving force behind rising US healthcare costs, and inpatient-based fees are significa

178 (CDI) is an important cause of morbidity and healthcare costs, and is characterized by high rates of

179 betes incidence, CVD events, direct diabetes healthcare costs, and mortality over 10 y.

180 omes, improve convenience, potentially lower healthcare costs, and possibly lead to much greater phys

181 utcomes, reducing adverse events, decreasing healthcare costs, and preventing further emergence of an

182 simulating individuals' long-term outcomes, healthcare costs, and quality of life based on their cha

183 vital statistics, data from health surveys, healthcare costs, and SSB price elasticity estimates as

184 ited States societal perspective, limited to healthcare costs, and using a 3% annual discount rate.

185 ons, an increased length of stay, increasing healthcare costs, and withdrawal of drugs from market.

186 Rising healthcare costs are becoming increasingly burdensome fo

187 More than 25% of healthcare costs are spent in the last year of life, and

188 2-THRIVE), but its net effects on health and healthcare costs are unknown.

189 healthcare resource utilization (HCRU), and healthcare costs are unknown.

190 significantly reduce both mortality and the healthcare costs associated with bacterial infections, i

191 The direct healthcare costs associated with CHC are high, increase

192 he morbidity and mortality and the resultant healthcare costs associated with chronic heart failure (

193 n of commitment may be a contributor to high healthcare costs associated with critically ill patients

194 f hospitalizations and deaths and increasing healthcare costs associated with ExPEC infections.

195 Given the healthcare costs associated with obesity (especially in

196 ction rules can help to substantially reduce healthcare costs associated with preoperative cardiac ri

197 dity following acute hospital discharge, but healthcare costs associated with this ongoing morbidity

198 cumulative burden of morbidity, and average healthcare costs at older ages.

199 responsible for a significant proportion of healthcare costs attributable to asthma and have a large

200 HBI was associated with significantly lower healthcare costs, attributable to fewer days of hospital

201 Consequently, healthcare costs ($AU3.93 vs. $AU5.53 million) were sign

202 ys (RR=1.57, 95% CI: 1.10, 2.03), and higher healthcare costs (beta=US$877, 95% CI: US$42, US$1713).

203 Despite critical care being a significant healthcare cost burden there remains a paucity of studie

204 itis C virus (HCV) infection increases total healthcare costs but the effect of the severity of liver

205 D is more time consuming resulting in higher healthcare costs, but is (cost-) effective on the long-t

206 (COPD) increase the risk of death and drive healthcare costs, but whether they accelerate loss of lu

207 s and 10-year risk >10%) would reduce annual healthcare costs by $430 million compared with Adult Tre

208 rs in approximately 14% and increases 1-year healthcare costs by >19,000 dollars per occurrence.

209 ated congestive heart failure (CHF), affects healthcare costs by hospital length of stay (LOS), readm

210 es but were sensitive to the level of annual healthcare costs caused by noncardiac diseases and to th

211 Health benefits and healthcare cost changes were also assessed in subgroups

212 reduce smoking should be part of short term healthcare cost containment.

213 Healthcare costs, coronary heart disease events, and qua

214 ic disease are significant, with both direct healthcare costs (doctor, nurse and dietitian consultati

215 , prevalence, attributable length of stay or healthcare cost due to hospital-acquired pressure ulcers

216 use and costs of cases; ii) to assess direct healthcare costs due to CD by comparing average resource

217 Sepsis is a leading contributor to excess healthcare costs due to hospital readmissions.

218 ality adjusted life years (QALYs) and direct healthcare costs expressed in 2012 euro.

219 s uninsured or underinsured, despite overall healthcare costs far above other nations.

220 c dialysis consumes a substantial portion of healthcare costs for a relatively small proportion of th

221 Total healthcare costs for adherent patients averaged $62 782

222 Lifetime healthcare costs for an HCV-infected person are signific

223 ermine the increased severity, mortality and healthcare costs for ceftiofur-resistant Salmonella Heid

224 ular disease, but also help reduce long-term healthcare costs for hospital stays, clinic visits and m

225 is translated to lower cumulative and annual healthcare costs for those in favorable cardiovascular h

226 mortality, hospital admissions and lifetime healthcare costs for those with PTSD.

227 This in turn can reduce healthcare costs, foster prodigious education, and stren

228 from the Global Burden of Disease Study; and healthcare costs from NHS England programme budgeting da

229 The dramatic increase in healthcare cost has become a significant burden to the w

230 associated with chronic hepatitis C (CHC) on healthcare costs has not been well studied.

231 percutaneous coronary intervention (PCI) on healthcare costs has not been well studied.

232 Rising healthcare costs have led to increasing focus on the nee

233 llergy testing was associated with decreased healthcare cost in four studies.

234 h these utilization data to calculate direct healthcare costs in 3 categories: consultation, medicati

235 ntact dermatitis, antibiotic resistance, and healthcare costs in conjunction with a low baseline rate

236 ms of amputation rates, quality of life, and healthcare costs in patients after femoropopliteal and f

237 Healthcare costs in patients with AR are markedly higher

238 tion is one of the causes of the increase in healthcare costs in the past few decades.

239 s not easily reversible, as well as the high healthcare costs inherent in device use, a clear underst

240 is is a priority given the high societal and healthcare costs involved.

241 standing the magnitude of postacute hospital healthcare costs is of increasing relevance to clinician

242 improves quality of life, but the effect on healthcare costs is unknown.

243 Given the rapidly rising healthcare costs, it is important to understand the econ

244 mplications for patients including increased healthcare costs, longer hospital stays, unnecessary con

245 thousands of people, leading to significant healthcare costs, loss of revenue for food companies, an

246 splant with subsequent clinical outcomes and healthcare costs may facilitate cost-benefit evaluations

247 In an era of ever-increasing healthcare costs, new treatments must not only improve o

248 self-testing would lead to modest savings in healthcare costs of $75 million, while averting around 7

249 he demographics, healthcare utilization, and healthcare costs of CHC patients in a large U.S. private

250 n mere temporal association, will reduce the healthcare costs of common diagnostic error.

251 Annual direct healthcare costs of COPD in England were estimated to in

252 South Africa) and 4.7% (Malawi) to five-year healthcare costs of tested patients, primarily reflectin

253 Few data are available on the healthcare costs of those suffering from persistent orof

254 When considering healthcare costs only, the program cost $25,500/QALY gai

255 ars, and save $31 billion (15.7-54.5) in net healthcare costs or $61.9 billion (33.1-103.3) societal

256 e compensation assumptions), limited data on healthcare costs other than those related to diabetes, a

257 ized GCPS status was predictive of increased healthcare cost over the last 6 mo, accounting for an av

258 were a significant proportion of cumulative healthcare cost (P < 0.001).

259 The average annual healthcare cost per faller was estimated at pound202 (in

260 Compared to SMC alone, the incremental healthcare cost per QALY was pound18,374 for CBT, pound2

261 ase Case: incremental short-term (days 1-28) healthcare costs per day-28 survivor; Panel on Cost-Effe

262 Average annual healthcare costs per patient increased by pound310 (95%

263 Total healthcare costs per patient substantially increase afte

264 edicine Reference Case: incremental lifetime healthcare costs per quality-adjusted life-year.

265 We primarily assessed total 3-year healthcare costs per quality-adjusted life-years at 3 ye

266 Mean all-cause and HCV-related healthcare costs per-patient-per-month (PPPM) during fol

267 significant implications for clinical care, healthcare costs, policy, and research.

268 ratios; DOC costs (2016 US dollars); and BI (healthcare cost/prison entrant) to generalize to other s

269 s (Total UC costs were defined as the sum of healthcare costs, productivity costs and out-of-pocket c

270 nd health-related costs (formal and informal healthcare costs, productivity costs) from established s

271 Healthcare cost reduction policies should consider the l

272 of interest, their relationship with overall healthcare costs remains largely unknown.

273 two large national healthcare databases: the Healthcare Cost Report Information System maintained by

274 s (HALYs) gained, and changes in IHD-related healthcare costs saved were estimated over 10 years and

275 a 20% tax on SSBs, the most HALYs gained and healthcare costs saved would accrue to the most disadvan

276 Health-adjusted life years (HALYs) gained, healthcare costs saved, and out-of-pocket costs were est

277 n QALYs gained, and $100.2 billion in formal healthcare costs saved, respectively.

278 zophrenia to clozapine indicated a potential healthcare cost saving of ~pound 3400 (equivalent to $42

279 substantial reduction in direct and indirect healthcare costs, saving US dollars 6462 per patient (p

280 ins of 175,300 (95% CI: 68,700; 277,800) and healthcare cost savings of AU$1,733 million (m) (95% CI:

281 ks to patients, and contributes to increased healthcare costs, stronger consideration of the role of

282 CD cases experienced higher healthcare costs than controls both before diagnosis (me

283 SMC patients had significantly lower healthcare costs than those receiving APT, CBT and GET.

284 million people worldwide, bringing the total healthcare cost to over 600 billion dollars per year.

285 ity, obesity-related diseases and associated healthcare costs to 2050.

286 Tying coverage for funeral expenses or healthcare costs to a family allowing organs to be procu

287 2, P<0.0001) than those who did not perceive healthcare costs to be burdensome.

288 individual's quality of life and incur high healthcare costs to society.

289 ment scorecards is associated with favorable healthcare cost trends, these data are not currently rob

290 overage on adherence, clinical outcomes, and healthcare costs using adjusted models among the 1052 pa

291 ls in the USA between 1997 and 2010 with the HealthCare Cost Utilization Project (HCUP) network datab

292 nwide Inpatient Sample (NIS) database of the Healthcare Cost Utilization Project (HCUP) to identify h

293 ermore, the association between payments and healthcare costs varies markedly across states and corre

294 Mean all-cause PPPM healthcare costs were 32% and 247% higher for patients w

295 Carer strain and healthcare costs were also recorded.

296 cluded, both heart failure-related and total healthcare costs were lower in the ISDN/HYD group (mean

297 e compliance, antimicrobial expenditure, and healthcare cost when an infectious disease fellow intera

298 Healthcare costs will be calculated by multiplying used

299 during EMR may lead to significantly higher healthcare cost without a clear clinical benefit.

300 entury, and is a major contributor to rising healthcare costs worldwide.